Cyfuse Biomedical K.K.
JPX: 4892.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Shizuka Akieda
- Employees
- 21
- Headquarters
- Tokyo, Japan
- IPO year
- 2022
- Market cap
- ¥5.7B
- Website
- https://www.cyfusebio.com
Loading 4892…
Loading profile data…Frequently asked questions about 4892
What does Cyfuse Biomedical K.K. (4892.T) do?
Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues...
Where does 4892.T trade?
Cyfuse Biomedical K.K. (4892.T) trades on the Tokyo Stock Exchange.
What sector is 4892.T in?
Cyfuse Biomedical K.K. (4892.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Cyfuse Biomedical K.K.?
Shizuka Akieda is the chief executive officer of Cyfuse Biomedical K.K. (4892.T).
Where is Cyfuse Biomedical K.K. headquartered?
Cyfuse Biomedical K.K. is headquartered in Japan.
Does 4892.T pay a dividend?
Cyfuse Biomedical K.K. (4892.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4892.T go public?
Cyfuse Biomedical K.K. (4892.T) completed its initial public offering in 2022.